What changed for Endometrial Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Endometrial Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 420 to 425 (+5)
- Trials on record 2,594 to 2,615 (+21)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Endometrial Cancer in July 2026. Voxsanity tracks 1 PBS-subsidised medicine for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 64 trials tracked for Endometrial Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04550429 · results posted 30 April 2026
According to the results reported on ClinicalTrials.gov, this trial looked at whether changing the operating pressure of a device called the MyoSure Hysteroscopic Morcellator — a tool used during a type of uterine procedure — affected things like the surgeon's ability to see clearly, how long the procedure took, and how much fluid was used. A total of 19 people took part: 11 were treated using the device set to a lower pressure (60 mmHg) and 8 were treated at a higher pressure (80 mmHg). The trial used a method called block randomisation, which means participants were assigned to each group by...
-
NCT02405221 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 participants in total — 8 received the TA-CIN vaccine injected into the thigh, and 7 received it injected into the arm. All participants had a history of HPV16-related cervical cancer (ranging from early to more advanced stages). The trial was primarily looking at whether the vaccine could be given safely via these two injection sites, and also measured certain immune system responses in the blood before and after vaccination. Twelve of the 15 participants completed the trial (6 in each group), with 3 not completin...
-
NCT04269200 · results posted 23 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04269200) enrolled people with newly diagnosed advanced or returning endometrial cancer (cancer of the lining of the uterus). A total of 718 participants took part in the main "Global Cohort" — 241 received standard chemotherapy alone (paclitaxel and carboplatin), 238 received chemotherapy plus a drug called durvalumab, and 239 received chemotherapy plus durvalumab and a second drug called olaparib. A separate smaller group of 129 people in China was also tracked. The trial was primarily measuring how long participants wen...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01676818 · results posted 6 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 people, all of whom received a treatment called eribulin mesylate. Thirty participants completed the study, while two did not. The trial was measuring two main things: how long participants went without their cancer getting worse (called progression-free survival), and how many participants experienced serious unwanted medical events (called serious adverse events) during treatment. The reported data shows that the median progression-free survival — meaning the middle point at which half of participants had experi...
-
NCT04363957 · results posted 14 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04363957) enrolled 80 people in total — 40 in each of two groups. One group went through a standard consent process before a type of internal radiation treatment called brachytherapy, while the other group went through the same standard consent process but also watched a video about the treatment. The trial was measuring how satisfied patients felt with the consent process and how anxious they felt about their treatment. The reported data shows that satisfaction was measured using a questionnaire with 12 questions, where...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03898167 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, this trial involved 2,474 people across three groups, all of whom were overdue for cervical cancer screening. The trial was measuring whether different ways of reaching out to these individuals would lead to more of them getting screened within six months. The three approaches tested were: a telephone reminder call, a mailed HPV self-sampling kit (where people collect their own sample at home), and a mailed HPV self-sampling kit combined with extra support from a patient navigator (someone who helps guide a person through the healthcare...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03104699 · results posted 30 July 2025
According to the results reported on ClinicalTrials.gov, this trial tested a drug called balstilimab across two phases. In Phase 1 (the dose-finding stage), 50 participants were split across five different dose levels, with 10 people in each group. In Phase 2 (the larger expansion stage), 161 participants all received what had been identified as the recommended dose. The trial was measuring things like how often serious side effects occurred at different doses, how the drug moved through the body at different dose levels, and — in Phase 2 — how many participants' tumours shrank or disappeared...
-
NCT04693234 · results posted 27 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04693234) enrolled 178 people in total across two groups: 138 people received a combination of two medicines called ociperlimab and tislelizumab (Cohort 1), and 40 people received tislelizumab on its own (Cohort 2). The trial was measuring what is called the "objective response rate" — that is, the proportion of participants whose tumours showed a confirmed shrinkage (either a complete disappearance or a partial reduction in size) according to standardised imaging criteria. The trial also looked at how long any such respon...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02684227 · results posted 19 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02684227) looked at a combination of three medicines — enzalutamide, carboplatin, and paclitaxel — in women with advanced or returning endometrial (uterine) cancer. The trial was split into two parts: a smaller safety lead-in group (Part A, 7 participants) and a larger main phase (Part B, 43 participants), giving a total of 50 participants across both parts. The trial was measuring how many tumours shrank or disappeared, how long participants went without their cancer getting worse, and how long participants survived overa...
-
NCT04300647 · results posted 7 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04300647) enrolled 172 participants in total. Before a planned crossover point, 45 people received a drug called atezolizumab on its own, and 127 people received atezolizumab combined with a second drug called tiragolumab. After the crossover, 17 participants moved to the combination treatment. The trial was primarily measuring the "objective response rate" — that is, the percentage of participants whose tumours shrank or disappeared by a defined amount, as assessed by an independent review committee. The reported data sh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04508309 · results posted 30 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,025 participants across five groups, each receiving two doses of an HPV (human papillomavirus) vaccine on different schedules. Four groups received two doses of Cecolin (a two-strain HPV vaccine) spaced either 6, 12, or 24 months apart, or a first dose of Gardasil (a four-strain HPV vaccine) followed by a Cecolin dose 24 months later. A fifth group received two doses of Gardasil 6 months apart. The trial was measuring the immune response — specifically, the level of antibodies (proteins the body produces in response...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02630823 · results posted 3 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02630823) involved 10 participants, all of whom received the study treatment, MK-3475 (also known as pembrolizumab). Eight of the 10 participants completed the study, while 2 did not complete it. The trial was primarily measuring the number of participants who experienced side effects that were considered related to the treatment. It also tracked a measure called progression-free survival — that is, the length of time from when treatment started until either the disease got worse or a participant passed away. The reported...
-
NCT03884101 · results posted 16 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03884101) enrolled 842 people — 420 in a group receiving lenvatinib plus pembrolizumab, and 422 in a group receiving paclitaxel plus carboplatin (a standard chemotherapy combination). The trial was measuring how long participants went without their cancer growing or spreading (called progression-free survival), how long participants overall survived, and what proportion of participants saw their tumours shrink or disappear. The trial looked at results both across all participants and within a specific subgroup whose tumour...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04551950 · results posted 8 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04551950) enrolled 25 people in total across three groups. Eight participants were in Cohort 1A, who received bintrafusp alfa combined with cisplatin or carboplatin, paclitaxel, and bevacizumab. Nine participants were in Cohort 1B, who received bintrafusp alfa with cisplatin or carboplatin and paclitaxel. Eight participants were in Cohort 2, who received bintrafusp alfa with cisplatin and radiotherapy. The trial was primarily measuring two things: how many participants experienced "dose-limiting toxicities" (that is, serio...
-
NCT04246489 · results posted 9 May 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 146 adults who received a drug called bintrafusp alfa. All 146 participants were recorded as having completed the study. The trial was measuring how their tumours responded to the treatment, using a standard set of imaging-based rules called RECIST v1.1, which classifies responses by looking at whether tumours shrank, stayed the same, or grew. The reported data shows that the main (primary) thing being measured was how many participants had a confirmed tumour response — meaning their tumours either disappeared entire...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01367002 · results posted 18 April 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 61 people in total — 29 in a group receiving a chemotherapy combination (carboplatin and paclitaxel) and 32 in a group receiving trastuzumab (a targeted medicine). The trial was looking at a type of uterine cancer called uterine serous papillary carcinoma (USPC). The main thing being measured was how long participants went without their cancer getting worse — known as "progression-free survival." The trial also recorded response to treatment, overall survival (how many people were still alive at the end of the study p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00492778 · results posted 29 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT00492778) involved 165 people in total — 82 in one group receiving brachytherapy (internal radiation) and radiation therapy alone, and 83 in a second group receiving the same radiation treatment plus a chemotherapy medicine called cisplatin. The trial was measuring how many participants experienced their disease getting worse or dying, how many died overall, and how many experienced significant side effects during and after treatment. The reported data shows that, for the main outcome — the number of people whose disease...
-
NCT03422198 · results posted 23 December 2022
According to the results reported on ClinicalTrials.gov, this trial involved 108 people who had been diagnosed with endometrial (uterine) cancer and were receiving a type of internal radiation treatment called vaginal cuff brachytherapy. Participants were split into two equal groups of 54: one group received a shorter course of this radiation treatment, and the other received the standard-length course. The trial was measuring quality of life, feelings about femininity, and the cost of treatment. All 108 participants who started the trial completed it. Please note that some planned measurement...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00923702 · results posted 20 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT00923702) enrolled a total of 22,729 participants across five groups: those who received three doses of the HPV vaccine (4,348 people), two doses (4,979 people), two doses by default (3,452 people), a single dose (4,950 people), and an unvaccinated comparison group (5,000 people). The trial was measuring antibody levels in the blood in response to the HPV vaccine types covered (HPV 16, 18, 6, and 11), as well as how often persistent HPV infection and HPV-related precancerous or cancerous cervical changes occurred across th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03103087 · results posted 20 April 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 382 women across three groups: 126 received relugolix combined with the hormones estradiol and norethindrone acetate (referred to here as "relugolix plus add-back hormones"), 127 received relugolix with the add-back hormones introduced after a short delay, and 129 received a placebo (inactive treatment). The trial ran for up to 24 weeks and was measuring several things related to uterine fibroids, including menstrual blood loss, period absence, pain, blood counts, and fibroid size. The pre-specified comparisons in the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03886220 · results posted 31 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03886220) looked at a medication called elagolix (150 mg) compared to a placebo (a dummy treatment with no active ingredient) in people with heavy menstrual bleeding related to uterine fibroids (non-cancerous growths in the womb). A total of 82 participants started the treatment period — 28 in the placebo group and 54 in the elagolix group. Of those, 65 completed the treatment period (23 and 42 respectively), and a follow-up period after treatment was also completed by most of those who entered it. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03196180 · results posted 23 February 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 women who had been diagnosed with high-grade cervical cell changes (abnormal cells on the cervix confirmed by biopsy). Eleven of the 13 participants completed the study, while two did not finish. The trial was testing whether it was practical and tolerable for women to apply two topical (applied directly to the skin/tissue) treatments — fluorouracil and imiquimod — inside the vagina on alternating weeks. Researchers also looked at whether the cervical cell changes showed any regression (improvement toward normal),...
-
NCT01706705 · results posted 23 February 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 57 participants, all of whom were in a single group receiving a specialised brachytherapy (internal radiation) treatment planning approach. Of those 57 people who started, 37 completed the study and 20 did not. The trial was measuring whether a novel applicator device — used to deliver internal radiation treatment — could produce better quality medical scan images when positioned in two different ways: a "shifted" position and a "standard" position. Image quality was assessed both by a radiation specialist reviewing t...
-
NCT03517449 · results posted 17 November 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03517449) enrolled 411 people in the lenvatinib plus pembrolizumab group and 416 people in the comparison group, who received a doctor-chosen chemotherapy (either doxorubicin or paclitaxel). The trial was measuring several things in people with a type of cancer called endometrial (uterine) cancer: how long participants went without their cancer growing or spreading (called progression-free survival), how long participants lived overall (called overall survival), and what proportion of participants saw their tumours shrink...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03438006 · results posted 8 September 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03438006) involved 3,013 participants who received the Cervarix vaccine (a cervical cancer vaccine). Of these, 2,895 completed the study and 118 did not. The trial was set up to track and count any unwanted health events — called adverse events following immunisation (AEFIs) — that occurred after each dose and across all doses combined. This included events serious enough to require an unplanned visit to a doctor or hospital. The reported data shows that, looking across all doses, 147 participants experienced a medically...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01536392 · results posted 17 May 2021
According to the results reported on ClinicalTrials.gov, this trial compared two anti-nausea medicines used during chemotherapy: a granisetron skin patch (worn on the body) and ondansetron tablets taken by mouth. A total of 41 people were enrolled in the skin patch group and 34 in the tablet group. Of those, 28 and 19 participants respectively completed the trial, meaning a notable number in both groups did not finish. The reported data shows that the trial measured how many participants had no vomiting or retching episodes and did not need any extra "rescue" anti-nausea medicine. This was lo...
-
NCT03400956 · results posted 30 April 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03400956) enrolled 103 participants across three groups. One group (35 people) received the drug vilaprisan continuously throughout the study. The other two groups (34 people each) took part in a crossover design — one group received a placebo first and then switched to vilaprisan, while the other received vilaprisan first and then switched to a placebo. The trial was looking at how vilaprisan affected menstrual bleeding in participants, particularly whether it stopped periods altogether and whether it reduced very heavy b...
-
NCT02354534 · results posted 2 April 2021
According to the results reported on ClinicalTrials.gov, this trial looked at artesunate suppositories (a medicine inserted into the vagina) in people with a cervical cell change called CIN2/3, which is caused by the human papillomavirus (HPV). A total of 30 people took part across four groups, receiving either a lower dose (50 mg for one treatment cycle) or a higher dose (200 mg for one, two, or three treatment cycles). The trial was primarily measuring whether the treatment caused any serious unwanted medical events, and secondarily whether HPV became undetectable and whether the abnormal ce...
-
NCT01365156 · results posted 3 February 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT01365156) enrolled 28 people with locally advanced cervical cancer — 14 in a surgery group and 14 in a chemoradiation group. All 28 participants were recorded as having completed the study with no drop-outs noted. The trial was set up to compare two approaches: one where patients first had a surgical procedure to check lymph nodes near the aorta (a large blood vessel in the abdomen) before receiving targeted chemoradiation (a combination of chemotherapy and radiation), versus a standard approach where imaging scans were us...
-
NCT02005510 · results posted 16 September 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02005510) looked at whether mailing an at-home HPV self-testing kit to people overdue for cervical cancer screening would lead to more of them getting screened, compared to people who received the usual care from their clinic. In the first round, 8,120 people were placed in the in-home HPV screening group and 8,111 in the usual care group. Smaller groups were re-randomised in two further rounds for those who still had not been screened. The reported data shows that when it came to completing cervical cancer screening, 2,6...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 64 reported results for Endometrial Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, endometrial cancer currently attracts a very large amount of public research investment from the United States government, and that investment has remained broadly steady from one year to the next. For patients, this pattern suggests that endometrial cancer is treated as an established and ongoing research priority rather than a newly emerging one. Sustained funding...
See the full Endometrial Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.